# US 2025/0375469 A1 · Formulations for improving gut health

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0375469 A1
- Document ID: US20250375469A1
- Status: Published application
- Kind: A1
- Application number: 19/312,760
- Filed: 2025-08-28
- Published: 2025-12-11
- Earliest claimed: 2018-08-29
- Assignees: Dsm IP Assets B.V.
- Applicants: Dsm IP Assets B.V.
- Inventors: Maaike Johanna BRUINS; Sophie FEHLBAUM; Thanh-Van PHAM; Kevin PRUDENCE; Robert STEINERT; Pietro CELI; Gilberto LITTA; Estefania PEREZ CALVO; Wilbert SYBESMA
- Web page: https://patentgrep.com/patent/US20250375469A1

## CPC

- A61K 31/714: Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
- A61K 31/015: carbocyclic
- A61K 31/07: Retinol compounds, e.g. vitamin A (retinoic acids A61K31/203)
- A61K 31/122: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K 31/197: the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid (carnitine A61K31/205)
- A61K 31/202: having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557)
- A61K 31/355: Tocopherols, e.g. vitamin E
- A61K 31/375: Ascorbic acid, i.e. vitamin C; Salts thereof
- A61K 31/4188: condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
- A61K 31/4415: Pyridoxine, i.e. Vitamin B6 (pyridoxal phosphate A61K31/675)
- A61K 31/455: Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A61K 31/51: Thiamines, e.g. vitamin B1
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/525: Isoalloxazines, e.g. riboflavins, vitamin B2
- A61K 31/593: 9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 3/02: Nutrients, e.g. vitamins, minerals
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Various benefits to intestinal health are made by delivery of an active agent to the colon of an animal, including a human. Active ingredients include of riboflavin, vitamin A, vitamin C, vitamin D, vitamin E, vitamin K, folic acid, β-carotene, vitamin B1, niacin, vitamin B5, vitamin B6, biotin, vitamin B12, omega-3 fatty acids and combinations thereof. Benefits include increased concentration of at least one short-chain fatty acid its salt thereof in the intestine, increased microbiome diversity in the intestine, increased beneficial bacteria in the intestine, increased the butyrate synthesis pathway in the intestine, improved barrier function of the intestine, reduced redox potential of the gut, reduced amount of gas produced in the intestine; and stimulation of intestinal immune responses.

## Claims

### Claim 1

An active agent selected from the group consisting of riboflavin, vitamin A, vitamin C, vitamin D, vitamin E, vitamin K, folic acid, β-carotene, vitamin B1, niacin, vitamin B5, vitamin B6, biotin, vitamin B12, omega-3 fatty acids and combinations thereof, for use in improving intestinal health in an animal, including a human, wherein said improvement comprises or consists of
i. increasing the concentration of at least one short-chain fatty acid or a salt thereof in the intestine,
ii. increasing microbiome diversity in the intestine,
iii. increasing the abundance of a beneficial bacteria in the intestine,
iv. promoting or increasing the butyrate synthesis pathway in the intestine,
v. improving the barrier function of the intestine,
vi. reducing the redox potential of the gut,
vii. reducing the amount of gas produced in the intestine, and/or
viii. stimulating intestinal immune responses;
wherein said use comprises administering to the animal
a) a formulation comprising an effective dose of the active agent, wherein the active agent is delivered to the large intestine; or
b) a supra physiological dose of an active ingredient so that at least an effective amount of the active ingredient is present in the animal's intestine;
with the provisos that if niacin is present it is not the sole active ingredient; and if riboflavin is present it has an improving effect other than increasing the amount of Faecalibacterium prausnitzii.

### Claim 2 (depends on 1)

An active agent according to claim 1, wherein the animal is a human and the effective dose of the active agent is delivered by a delayed release formulation.

### Claim 3 (depends on 1, 2)

An active agent according to claim 1 or 2, wherein the improvement comprises increasing the concentration of at least one short-chain fatty acid or a salt thereof in the intestine; or promoting or increasing the butyrate synthesis pathway in the intestine;
and wherein the short-chain fatty acid is selected from the group consisting of: of acetic acid, propionic acid and butyric acid or salts thereof.

### Claim 4 (depends on 3)

An active agent according to claim 3, wherein the active agent is selected from the group consisting of: Vitamin A, beta carotene, Vitamin C, riboflavin, Vitamin D, Vitamin E, Vitamin K, folic acid, omega 3 fatty acids, and combinations thereof.

### Claim 5 (depends on 3, 4)

An active agent according to claim 3 or 4, wherein the animal, including a human is experiencing a condition selected from the group consisting of: metabolic disorder, Type 2 Diabetes, obesity, chronic inflammation, and atherogenesis.

### Claim 6 (depends on 1, 2)

An active agent according to claim 1 or 2, wherein the improvement comprises increasing microbiome diversity in the intestine.

### Claim 7 (depends on 6)

An active agent according to claim 6, wherein the microbiome diversity is increased and/or the abundance of beneficial bacteria are increased in the colon.

### Claim 8 (depends on 6, 7)

An active agent according to claim 6 or 7, wherein the beneficial bacteria which are increased are selected from the group consisting of: Acidaminococcus, Akkermansia sp. Bacteroides ovatus, Bifidobacterium spp., Blautia producta, Clostridium cocleatum, Collinsella aerofaciens, Dorea longicatena, Escherichia coli, Eubacterium spp., Faecalibacterium prausnitzii, Lachnospira pectinoshiza, Lactobacillus spp., Parabacteroides distasonis, Raoultella spp., Roseburia spp., Ruminococcus spp., Streptococcus spp., and combinations thereof.

### Claim 9 (depends on 6, 7, 8)

An active agent according to any of claims 6 to 8, wherein the bacteria which are increased are selected from the group consisting of Bifidobacterium, Akkermansia, Faecalibacterium and Bacteroides.

### Claim 10 (depends on 6, 7, 8, 9)

An active agent according to any of claims 6-9, wherein the animal, including a human, is experiencing a condition selected from the group consisting of: irritable bowel disease, metabolic disease, obesity, and inflammatory conditions.

### Claim 11 (depends on 6, 7, 8, 9, 10)

An active agent according to any of claims 6-10, wherein the agent is selected from the group consisting of: Vitamin B1, Vitamin B2, Vitamin B5, Vitamin B6, Vitamin B12, Beta-carotene, biotin, Vitamin C, Vitamin E, Vitamin D, folic acid, Vitamin K, omega 3 fatty acids, and combinations thereof.

### Claim 12 (depends on 1, 2)

An active agent according to claim 1 or 2, wherein the improvement comprises improving the barrier function of the intestine.

### Claim 13 (depends on 12)

An active agent according to claim 12, wherein the animal including the human is experiencing a condition selected from the group consisting of: irritable bowel disease, Chron's disease, ulcerative colitis, leaky gut, and malnutrition.

### Claim 14 (depends on 12, 13)

An active agent according to claim 12 or 13, wherein the active agent is selected from the group consisting of: Vitamin B2, Vitamin C, Vitamin E, omega-3 fatty acids, Vitamin D, Vitamin A, folic acid, Vitamin K1 and mixtures thereof.

### Claim 15 (depends on 1, 2)

An active agent according to claim 1 or 2, wherein the improvement comprises reducing the redox potential of the gut.

### Claim 16 (depends on 15)

An active agent according to claim 15, wherein the reduced redox potential results in a benefit selected from the group consisting of: promoted growth of strictly anerobic beneficial bacteria in the colon; reduction of aerotolerant pathogenic organisms in the gut, lowering of plasma free thiols, decreased inflammation in the gut, and decrease in cell damage resulting from inflammation in the gut.

### Claim 17 (depends on 15, 16)

An active agent according to claim 15 or 16, wherein the active agent is selected from the group consisting of Vitamin C, Vitamin E and mixtures thereof.

### Claim 18 (depends on 1, 2)

An active agent according to claim 1 or 2, wherein the improvement is reducing the amount of gas produced in the intestine.

### Claim 19 (depends on 18)

An active agent according to claim 18, wherein the active agent is Vitamin B2, Vitamin C, Vitamin E and combinations thereof.

### Claim 20 (depends on 1, 2)

An active agent according to claim 1 or 2, wherein the improvement is stimulating the intestinal immune responses.

### Claim 21 (depends on 20)

An active agent according to claim 20, wherein the immune response is an increase in an immune response molecule selected from the group consisting of: GROa-CXCL1, MIP3A-CCL20, Interleukin 8, and a combination of thereof.

### Claim 22 (depends on 20, 21)

An active agent according to claim 20 or 21, wherein the active agent is selected from the group consisting of: Vitamin B2, Vitamin E, Vitamin D, Vitamin A, and Vitamin K, and mixtures thereof.

### Claim 23

A method of improving intestinal health in an animal, including a human, wherein said improvement comprises or consists of
i increasing the concentration of at least one short-chain fatty acid or a salt thereof in the intestine,
ii increasing microbiome diversity in the intestine,
iii. increasing the abundance of a beneficial bacteria in the intestine,
iv. promoting or increasing the butyrate synthesis pathway in the intestine,
v. improving the barrier function of the intestine,
vi reducing the redox potential of the gut,
vii reducing the amount of gas produced in the intestine, and/or
viii stimulating intestinal immune responses;
comprising administering to the animal an active agent selected from the group consisting of riboflavin, vitamin A, vitamin C, vitamin D, vitamin E, vitamin K, folic acid, β-carotene, vitamin B1, niacin, vitamin B5, vitamin B6, biotin, vitamin B12, omega-3 fatty acids and combinations thereof, wherein the active agent is present in
a) a formulation comprising an effective dose of the active agent, wherein the active agent is delivered to the large intestine; or
b) a supra physiological dose of an active ingredient so that at least an effective amount of the active ingredient is present in the animal's intestine;
with the provisos that if niacin is present it is not the sole active ingredient; and if riboflavin is present it has an improving effect other than increasing the amount of Faecalibacterium prausnitzii.

### Claim 24 (depends on 23)

The method according to claim 23, wherein the animal is a human and the active agent is delivered to the intestine.

### Claim 25 (depends on 23)

The method according to claim 23, wherein the active agent is in a supra physiological dose.

### Claim 26 (depends on 23)

The method according to claim 23, wherein the improvement is increasing at least one short-chain fatty acid and/or increasing the butyrate synthesis pathway activity in an animal.

### Claim 27 (depends on 26)

The method according to claim 26, wherein the animal is experiencing a condition selected from the group consisting of metabolic disorders, Type 2 diabetes, obesity, chronic inflammation and arterogenesis.

### Claim 28 (depends on 26)

The method according to claim 26, comprising administering at least one active agent selected from the group consisting of Vitamin A, Vitamin C, riboflavin, Vitamin E, folic acid, beta-carotene, omega 3 fatty acids and combinations thereof.

### Claim 29 (depends on 23)

The method according to claim 23, wherein the improvement is increasing microbiome diversity in the intestine, or increasing the abundance of a beneficial bacteria in the intestine,

### Claim 30 (depends on 29)

The method according to claim 29, wherein the active agent is selected from the group consisting of: Vitamin B1, riboflavin, Vitamin B5, Vitamin B12, beta-carotene, biotin, Vitamin C, Vitamin E, Vitamin D, folic acid, Vitamin K, omega 3 fatty acids, and combinations thereof; with the proviso that if riboflavin is an active agent, then it is present for a purpose other than increasing the abundance of F. prausnitzii.

### Claim 31 (depends on 29)

The method according to claim 29, which is a method of treating, preventing, or lessening the symptoms of irritable bowel syndrome, metabolic disease, obesity, or inflammatory conditions in an animal including a human in need thereof comprising: administering a beneficial bacteria enhancing amount of an active agent to the colon of the animal; the active agent being selected from the group consisting of: Vitamin B1, riboflavin, Vitamin B5, Vitamin B12, beta-carotene, biotin, Vitamin C, Vitamin E, Vitamin D, folic acid, Vitamin K, omega 3 fatty acids, and combinations thereof; with the proviso that if riboflavin is an active agent, then it is present for a purpose other than increasing the abundance of F. prausnitzii.

### Claim 32 (depends on 23)

The method according to claim 23, wherein the improvement is stimulating intestinal immune responses.

### Claim 33 (depends on 32)

The method according to claim 32, wherein the animal including a human is experiencing acute or chronic inflammation.

### Claim 34 (depends on 33)

The method according to claim 33, wherein the active agent selected from the group consisting of riboflavin, Vitamin E, Vitamin A Vitamin K and combinations thereof.

### Claim 35 (depends on 32)

The method according to claim 32, wherein the improvement is reducing the redox potential of the gut, which results in a benefit selected from the group consisting of:
promoting growth of strictly anerobic beneficial bacteria in the colon;
reducing aerotolerant pathogenic organisms in the gut;
decreasing the inflammation in the gut; and
decreasing cell damage in the gut resulting from inflammation in the gut.

### Claim 36 (depends on 35)

The method according to claim 35, wherein the agent is selected from the group consisting of riboflavin, Vitamin C, Vitamin E and mixtures thereof.

### Claim 37 (depends on 23)

The method according to claim 23, wherein the improvement is of treating, preventing, or lessening the amount of gas produced in the gut.

### Claim 38 (depends on 23, 37)

The method according to claim 23 or 37, wherein the active agent is selected from the group consisting of Vitamin B2, Vitamin C and combinations thereof.

### Claim 39 (depends on 23)

The method according to claim 23, wherein the improvement is improving gut barrier function.

### Claim 40 (depends on 39)

The method according to claim 39, wherein the improving the barrier function is a method of of treating, preventing or lessening the symptoms of a condition selected from the group consisting of irritable bowel disease, Crohn's disease, ulcerative colitis, leaky gut and malnutrition.

### Claim 41 (depends on 40)

The method according to claim 40, wherein the agent is selected from the group consisting of: riboflavin, vitamin C, Vitamin E, omega-3 fatty acids, Vitamin D, Vitamin A, folic acid, Vitamin K and mixtures thereof.
